Rothschild & CO Asset Management Us Inc. Bluebird Bio, Inc. Transaction History

Rothschild & CO Asset Management Us Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 05, 2019	SELL	$59.1 - $93.26 $177,418 - $279,966	-3,002 Closed	0 $0
Q2 2018 Aug 07, 2018	SELL	$99.64 - $127.59 $3.43 Million - $4.4 Million	-34,457 Reduced 91.99%	3,002 $471,000
Q1 2018 May 08, 2018	SELL	$105.8 - $150.94 $209,060 - $298,257	-1,976 Reduced 5.01%	37,459 $6.4 Million
Q4 2017 Feb 12, 2018	BUY	$81.25 - $130.7 $3.2 Million - $5.15 Million	39,435	39,435 $7.02 Million

112

61.5M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $485M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Rothschild & CO Asset Management Us Inc., based on Form 13F filings with the SEC.

Stay updated on Rothschild & CO Asset Management Us Inc. with notifications on news.